These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 32301356)
21. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Ryan NM; Vertigan AE; Birring SS Expert Opin Pharmacother; 2018 May; 19(7):687-711. PubMed ID: 29658795 [TBL] [Abstract][Full Text] [Related]
23. ATP, an attractive target for the treatment of refractory chronic cough. Zhang M; Sykes DL; Sadofsky LR; Morice AH Purinergic Signal; 2022 Sep; 18(3):289-305. PubMed ID: 35727480 [TBL] [Abstract][Full Text] [Related]
24. The current and emerging treatment landscape for chronic cough. Dicpinigaitis P Am J Manag Care; 2022 Sep; 28(9 Suppl):S159-S165. PubMed ID: 36198074 [TBL] [Abstract][Full Text] [Related]
25. The problem of cough and development of novel antitussives. Barnes PJ Pulm Pharmacol Ther; 2007; 20(4):416-22. PubMed ID: 17189707 [TBL] [Abstract][Full Text] [Related]
26. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP; Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425 [TBL] [Abstract][Full Text] [Related]
27. Chronic cough. Wee B Curr Opin Support Palliat Care; 2008 Jun; 2(2):105-9. PubMed ID: 18685405 [TBL] [Abstract][Full Text] [Related]
34. Codeine: A Relook at the Old Antitussive. Vora A; Nadkar MY J Assoc Physicians India; 2015 Apr; 63(4):80, 82-5. PubMed ID: 26591180 [TBL] [Abstract][Full Text] [Related]
35. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965 [TBL] [Abstract][Full Text] [Related]
36. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Garceau D; Chauret N Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655 [TBL] [Abstract][Full Text] [Related]
37. Gefapixant: First Approval. Markham A Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of Gefapixant, a P2X Ishiura Y; Nomura S; Ishii Y; Imai K; Sawai Y; Tamaki T; Shimizu T; Miyashita N; Ito T Int Med Case Rep J; 2023; 16():497-501. PubMed ID: 37692174 [TBL] [Abstract][Full Text] [Related]
39. Current and future prospects for drugs to suppress cough. Chung KF IDrugs; 2003 Aug; 6(8):781-6. PubMed ID: 12917774 [TBL] [Abstract][Full Text] [Related]
40. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups. Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]